Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Most human 7SL RNA sequences found in the genome are pseudogenes, dispersed copies that result from retrotransposition or other molecular mechanisms, and are generally truncated, nonfunctional fragments of the authentic SRP RNA gene[1]. RN7SL263P specifically designates one such locus, with no demonstrable transcriptional activity or biological function. Mislabeling it with aliases such as "breakpoint cluster region protein" (BCR) or linking it to the BCR protein is incorrect, as BCR is a distinct protein-coding gene—a kinase involved in intracellular signaling and oncogenic fusion proteins—that bears no relation to 7SL RNA pseudogenes[2][6]. Only the true 7SL RNA gene encodes the scaffold RNA of the signal recognition particle, essential for cotranslational membrane protein targeting[3][7]. Pseudogenes like RN7SL263P have no current utility as drug targets, disease biomarkers, or functional RNAs.
None; not drug-targetable.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 263, pseudogene (RN7SL263P).